2024-519651-28-00CompletedPhase 1
A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Jun 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 17 Feb 2025
- Start date
- 5 Aug 2025
- Lead sponsor
- CureVac SE
- Diseases
- Lung cancer
- EU CT number
- 2024-519651-28-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 12 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (12)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Quirónsalud Barcelona | Barcelona | Spain | Completed |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Hospital Universitario HM Sanchinarro | Madrid | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz | Madrid | Spain | Completed |
| Hospital Universitario Virgen de la Victoria | Málaga | Spain | Completed |
| Institut Bergonie | Bordeaux | France | Completed |
| Centre Hospitalier Regional De Marseille | Marseille | France | Completed |
| Institut Curie | Paris | France | Completed |
| Centre Hospitalier Universitaire de Rennes | Rennes | France | Completed |
| Institut De Cancerologie De L Ouest | Saint-Herblain Cedex | France | Completed |
| Oncopole Claudius Regaud | Toulouse | France | Completed |
| Institut Gustave Roussy | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.